ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
R03DX10 | B | Benralizumab - 30mg | 10762 | 128820/1 | FASENRA | 30mg | 1 | Injectable solution | SC | Omnipharma | Catalent Indiana, LLC | USA | 3,513,619 L.L | 2.44 | E2 | AstraZeneca AB | Sweden | 1/4/2023 |
ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
R03DX10 | B | Benralizumab - 30mg | 10144 | 115719/1 | FASENRA | 30mg | 1 | Injectable solution | SC | Omnipharma | Catalent Indiana, LLC | USA | 3,521,007 L.L | 2.44 | E2 | AstraZeneca AB | Sweden | 1/4/2023 |